Als Cure Project Inc
- Assets
- $98.3k
- Revenue
- $164.5k
- Investments
- $0.0
- Employees
- 0
- Location
- Pleasanton, CA
- Founding
- 11/2019
- Data as of
- 12/2023
- EIN
- 84-3289802
Organization Overview
Als Cure Project Inc is located in Pleasanton, CA. The organization was established in 2019. According to its NTEE Classification (H50) the organization is classified as: Nerve, Muscle & Bone Diseases Research, under the broad grouping of Medical Research and related organizations. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Als Cure Project Inc is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2023, Als Cure Project Inc generated $164.5k in total revenue. This represents a relatively dramatic decline in revenue. Over the past 4 years, the organization has seen revenues fall by an average of (25.1%) each year. All expenses for the organization totaled $244.3k during the year ending 12/2023. You can explore the organizations financials more deeply in the financial statements section below.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2023
Describe the Organization's Mission:
Part 3 - Line 1
THE SPECFIC PURPOSE OF THE ORGANIZATION SHALL INCLUDE WITHOUT LIMITATION, TO LEAD SCIENTIFIC RESEARCH FOCUSED ON THE IDENTIFICATION OF AMYOTROPHIC LATERAL SCIEROSIS ALS BIO-MARKERS AND DISEASE MECHANISM
Describe the Organization's Program Activity:
Part 3 - Line 4a
ALS CURE PROJECT CONTINUED TO FUND THE PHYSICS BASED MODELING PROJECT USING THE WORLDS FASTEST SUPERCOMPUTER AT LAWERANCE LIVERMORE LAB TO HELP IDENITY AND UNDERSTAND THE ALS DISEASE MECHANISM. THE INITIAL FOCUS WILL BE ON THE FORMATION OF THE ABERRANT TAR DNA- BINDING PROTIEN 43 TDP-43 INCLUSIONS OR CLUSTER THAT TRANSITION INTO PATHOLOGICAL, AMYYLOID-LIKE FIBRILS
ALS CURE PROJECT FUNDED SEED RESEARCH IN ORGANOIDS AND ASSEMBLOIDS FROM THE 2023 INNOVATION SYMPOSIUM THAT WE HOST. THE RESEARCH WILL USE CORTICO-MOTOR ASSEMBLOIDS TO INVESTIGATE THE CONTRIBUTION OF CORTICAL NEURONAL HYPERACTIVITY TO ALS PHENTYPES, TO ULTIMATELY PINPOINT MOLECULAR PATHWAYS CONTRIBUTING TO MOTOR NEURON DEGENERATION
THE ALS CURE PROJECT SEEDED 2 RESEARCH PROJECT BARROW NEURO AND TRIPARITE SELECTED FROM THE ALS INNOVATION SYMPOSIM HELD VIRTUAL ON NOVEMBER 17TH AND DECEMBER 1STOF 2021 THAT INCLUDED 115 INTERNATIONAL ALS RESEARCHERS FROM 10 NATIONS WHERE PARTICIPANTS WORKED COLLABORATIVELY IN WORKSHOP STYLED BREAKOUTS TO CREATE THE SYMPOSIUMS PRODUCT. THE EVENT WAS ALSO CO-SPONSORED BY MITSUBISHI TANABE PHARMA AMERICA MTPA
Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.
PDF Copies of 990 Filings
Board, Officers & Key Employees
| Name (title) | Role | Hours | Compensation |
|---|---|---|---|
Mike Piscotty President | OfficerTrustee | 10 | $0 |
Stephen Piscotty Vice President | Trustee | 1 | $0 |
Toni Eslick Secretary | Trustee | 6 | $0 |
James Gilbreth Fund Raising Director | Trustee | 6 | $0 |
Barron Wesenberg Treasurer | Trustee | 3 | $0 |
Andrew Woodward It Communications Director | Trustee | 3 | $0 |
Financial Statements
| Statement of Revenue | |
|---|---|
| Federated campaigns | $0 |
| Membership dues | $0 |
| Fundraising events | $51,469 |
| Related organizations | $0 |
| Government grants | $0 |
| All other contributions, gifts, grants, and similar amounts not included above | $0 |
| Noncash contributions included in lines 1a–1f | $0 |
| Total Revenue from Contributions, Gifts, Grants & Similar | $51,469 |
| Total Program Service Revenue | $0 |
| Investment income | $0 |
| Tax Exempt Bond Proceeds | $0 |
| Royalties | $0 |
| Net Rental Income | $0 |
| Net Gain/Loss on Asset Sales | $0 |
| Net Income from Fundraising Events | $113,020 |
| Net Income from Gaming Activities | $0 |
| Net Income from Sales of Inventory | $0 |
| Miscellaneous Revenue | $0 |
| Total Revenue | $164,489 |
| Statement of Expenses | |
|---|---|
| Grants and other assistance to domestic organizations and domestic governments. | $238,000 |
| Grants and other assistance to domestic individuals. | $0 |
| Grants and other assistance to Foreign Orgs/Individuals | $0 |
| Benefits paid to or for members | $0 |
| Compensation of current officers, directors, key employees. | $0 |
| Compensation of current officers, directors, key employees. | $0 |
| Compensation to disqualified persons | $0 |
| Other salaries and wages | $0 |
| Pension plan accruals and contributions | $0 |
| Other employee benefits | $0 |
| Payroll taxes | $0 |
| Fees for services: Management | $0 |
| Fees for services: Legal | $0 |
| Fees for services: Accounting | $0 |
| Fees for services: Lobbying | $0 |
| Fees for services: Fundraising | $0 |
| Fees for services: Investment Management | $0 |
| Fees for services: Other | $0 |
| Advertising and promotion | $0 |
| Office expenses | $2,388 |
| Information technology | $2,395 |
| Royalties | $0 |
| Occupancy | $0 |
| Travel | $0 |
| Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
| Conferences, conventions, and meetings | $0 |
| Interest | $0 |
| Payments to affiliates | $0 |
| Depreciation, depletion, and amortization | $0 |
| Insurance | $1,545 |
| All other expenses | $0 |
| Total functional expenses | $244,328 |
| Balance Sheet | |
|---|---|
| Cash—non-interest-bearing | $98,318 |
| Savings and temporary cash investments | $0 |
| Pledges and grants receivable | $0 |
| Accounts receivable, net | $0 |
| Loans from Officers, Directors, or Controlling Persons | $0 |
| Loans from Disqualified Persons | $0 |
| Notes and loans receivable | $0 |
| Inventories for sale or use | $0 |
| Prepaid expenses and deferred charges | $0 |
| Net Land, buildings, and equipment | $0 |
| Investments—publicly traded securities | $0 |
| Investments—other securities | $0 |
| Investments—program-related | $0 |
| Intangible assets | $0 |
| Other assets | $0 |
| Total assets | $98,318 |
| Accounts payable and accrued expenses | $0 |
| Grants payable | $0 |
| Deferred revenue | $0 |
| Tax-exempt bond liabilities | $0 |
| Escrow or custodial account liability | $0 |
| Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
| Secured mortgages and notes payable | $0 |
| Unsecured mortgages and notes payable | $0 |
| Other liabilities | $0 |
| Total liabilities | $0 |
| Net assets without donor restrictions | $98,318 |
| Net assets with donor restrictions | $0 |
| Capital stock or trust principal, or current funds | $0 |
| Paid-in or capital surplus, or land, building, or equipment fund | $0 |
| Retained earnings, endowment, accumulated income, or other funds | $0 |
| Total liabilities and net assets/fund balances | $98,318 |
Grants Awarded
Over the last fiscal year, Als Cure Project Inc has awarded $238,000 in support to 4 organizations.
| Grant Recipient | Amount |
|---|---|
LIVERMORE LAB FOUNDATION PURPOSE: Bio Markers Research and ALS Symposium | $65,000 |
STANFORD UNIVERSITY PURPOSE: Multimodal Analysis | $73,000 |
EMORY UNIVERSITY PURPOSE: Organoid and Assembloid Research | $50,000 |
UNIVERSITY MEDICAL CENTER UTRECHT PURPOSE: Organoid and Assembloid Research | $50,000 |